Evidence map›Paper›PMID 41079737›Full record

ArticleFrontiers in pharmacology2025

Pretreatment with

Niqi Shan, Linxiao Wang, Chujun Duan, Yilin Wu, Yangmengjie Jing, Hanyin Fan, Shuai Wang, Yuling Wang, Shijia Wang, Hui Liu and 4 more

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Niqi Shan *Department of Immunology, Fourth Military Medical University, Xi'an, Shaanxi, China.
Linxiao Wang *Department of Emergency, Honghui Hospital, Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Chujun DuanDepartment of Immunology, Fourth Military Medical University, Xi'an, Shaanxi, China.
Yilin WuDepartment of Immunology, Fourth Military Medical University, Xi'an, Shaanxi, China.
Yangmengjie JingDepartment of Immunology, Fourth Military Medical University, Xi'an, Shaanxi, China.
Hanyin FanDepartment of Immunology, Fourth Military Medical University, Xi'an, Shaanxi, China.
Shuai WangDepartment of General Surgery, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Yuling WangDepartment of Immunology, Fourth Military Medical University, Xi'an, Shaanxi, China.
Shijia WangDepartment of Immunology, Fourth Military Medical University, Xi'an, Shaanxi, China.
Hui LiuDepartment of General Surgery, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Kun ChengDepartment of Immunology, Fourth Military Medical University, Xi'an, Shaanxi, China.
Lin LiuDepartment of Emergency, Honghui Hospital, Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Shanshou LiuDepartment of Emergency, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Ran ZhuangDepartment of Immunology, Fourth Military Medical University, Xi'an, Shaanxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Heat stroke (HS) is a life-threatening illness. For HS, prevention is more important than treatment. Methods: Mice were randomized to different groups. After 1 week of APS treatment, a mouse HS model was constructed and evaluated. Intestinal injury was assessed via histopathological examination, and the inflammation level was quantified via quantitative PCR. Flow cytometry and immunofluorescence analyses were used to detect neutrophil infiltration. Gut microbiota was analyzed via 16S rRNA sequencing. Moreover, network pharmacology was employed to analyze the potential targets and functional enrichment of APS. The apoptosis levels were detected in mouse intestinal tissues and IEC-6 intestinal epithelial cells. Results: APS pretreatment (50 mg/kg BW) prolonged the survival time, delayed the increasing rate of core temperature, and markedly improved organ injuries of HS mice. APS pretreatment improved the pathological changes in the intestine, inhibited inflammation, and reduced neutrophil infiltration. APS enhances the richness of intestinal flora and may shift microbiota functions, thereby benefiting vitamin B metabolism. Network pharmacology analysis indicated the apoptosis pathway as a potential target of APS. Conclusion: The preventive effects of APS on HS-induced intestinal injury include the alteration of intestinal microbiota composition and anti-inflammatory and antiapoptotic capacity.

Indexed as

apoptosisAstragalus polysaccharidesheat strokeintestinal immunitymicrobiomepharmacological network

Identifiers

PMID41079737
PMCPMC12510818

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.